27th January 2023
Latest news
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
21st December 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th November 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd November 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th November 2022
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
18th August 2022
NRG and Curium Sign Multi-Year Isotope Production Contract
27th June 2022
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
12th May 2022
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
3rd May 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th April 2022
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
5th April 2022
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
25th January 2022
Curium to become major player in the supply on non carrier added Lu-177
6th January 2022
Curium is attending these global congresses in 2022
15th December 2021
Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer
27th October 2021
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
24th August 2021
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
1st June 2021
Curium Acquires Austrian Radiopharmaceuticals Company IASON
5th May 2021
RadioMedix & Curium Announce Detectnet™ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
4th May 2021
Curium Announces Filing of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
28th April 2021